• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • About Us
  • Contact Us
  • Billing Portal
SPRINT® PNS System

SPR Therapeutics

SPRINT PNS System

  • Product
  • For Physicians
    • Clinical Outcomes & References
    • Implant Procedure Videos
    • Video Resources
    • SPRcare Reimbursement
    • Important Safety Information
    • MRI Safety Information
    • Promotional Marketing Toolkit
  • For Patients
    • Patient Stories
    • Patient Resources
    • Recursos para pacientes
    • MicroLead™ Safety
    • MRI Safety Information
  • Clinical Trials
  • News & Events
    • News
    • Events
    • Press Room
  • Careers

Prospective, Multicenter Study of Percutaneous Medial Branch PNS for the Treatment of Chronic Axial Low Back Pain

July 24, 2021

One of the most prevalent and challenging musculoskeletal conditions, chronic low back pain (LBP), is a leading cause of disability in adults.[1]

The SPRINT PNS System offers a motor-sparing 60-day peripheral nerve stimulation (PNS) treatment option for chronic axial low back pain. SPRINT PNS is designed to be used by pain physicians earlier in the treatment continuum than conventional neurostimulation.

Recently, Dr. Christopher Gilmore, an SPR Consultant, and colleagues sought to better understand how chronic low back pain patients who were recalcitrant to multiple non-surgical treatments would respond to 60-day PNS of the medial branch nerves. [View the full study].

“A lot of patients are opposed to surgical procedures, or at the least, would prefer to avoid undergoing invasive and permanent treatments,” Gilmore said. “Because of the non-surgical nature of temporary percutaneous PNS, we wanted to get in front of patients like this and characterize their responses so as to be able to improve our conversations with patients, and thereby help more individuals with chronic back pain.”

Can Medial Branch PNS Work for Patients Opposed to Surgical Treatments?

Patients suffering from low back pain and averse to invasive or destructive procedures may find temporary PNS a good option. Gilmore, et al., chose patients with broad eligibility criteria in an effort to characterize their response to a 60-day medial branch PNS treatment.

Key eligibility criteria included:

  • Subjects with chronic axial LBP (≥3 months) without radicular pain
  • Stable medication usage for ≥ 1 month prior to baseline
  • No prior lumbar surgery or RFA within prior 6 months
  • No anesthetic injections within prior 3 months
  • Score of ≤20 on Beck Depression Inventory

Participants were treated with the SPRINT PNS System using ultrasound and/or fluoroscopy guidance to place bilateral, percutaneous PNS leads targeting the medial branches of the dorsal ramus centered in the region of pain.


Stimulation of the medial branch was confirmed by selective activation of multifidi. Participants received stimulation for 6–12 hours a day for up to 60 days and continued most normal activities throughout the treatment period. They also participated in long-term follow-up visits up to 12 months post-treatment.

Medial Branch PNS Provided Significant Reductions in Pain Intensity and Interference

The majority of participants who completed the Primary Endpoint and long-term follow-up visits reported clinically meaningful and statistically significant reductions in pain, disability, and pain interference. These reductions were sustained for a majority of participants through 14 months from start of treatment.

Reductions in Average Pain Intensity (BPI-5)

A total of 73% of participants were responders to the PNS treatment reporting ≥ 30% pain intensity reduction after two months; responders experienced, on average, a 58% reduction in pain intensity.  At 14 months from the start of treatment, 50% of subjects (25 of 50 who have completed follow-up to date) continued to experience meaningful improvements in pain intensity.

Reductions in Oswestry Disability Index (ODI)

Additionally, 73% of participants experienced clinically meaningful reductions in back pain-related disability after two months of percutaneous PNS. Responders reported an average 21-pt reduction.  At 14 months from the start of treatment, 50% of subjects (25 of 50 who have completed follow-up to date) continued to experience meaningful improvements in disability.

Reductions in Pain Interference (BPI-9)

Following two months of percutaneous PNS, 73% of participants experienced clinically meaningful reductions in the interference of pain with daily activities, as measured by pain interference. Responders reported an average reduction of 67% pain interference.   At 14 months from the start of treatment, 58% of subjects (29 of 50 who have completed follow-up to date) continued to experience meaningful improvements in pain interference.

I

Medial Branch PNS Improved Health-Related Quality of Life

In addition to evaluating pain intensity, pain disability, and pain interference, Gilmore, et al., also asked participants to share how the PNS treatment impacted their quality of life (QoL). Using the Patient Global Impression of Change (PGIC) options (Very Much, Much, or Minimally Improved, No Change, Minimally, Much, or Very Much Worse), 90.5% of responders reported quality of life improvements.

Selected subscales from the RAND-36 measure of health-related quality of life were also used to identify statistically significant improvements in quality of life with percutaneous PNS. The table below shows the relevant subscales and marks of improvement in responders (**p < 0.001).

Selected RAND-36 SubscalesImprovement from Baseline
Role Limitations – Physical Health128%, 28.1 points**
Pain62%, 22.1 points**
Physical Functioning33%, 14.0 points**
Energy/Fatigue32%, 13.2 points **

A Majority of Participants Receiving Medial Branch PNS Reduced or Stopped Opioid Usage

A final promising result from this study was the percentage of participants who either reduced opioid consumption or ceased using opioids for pain relief altogether at the end of the PNS treatment.

Participants reported:

  • 63% reduced opioid usage (with an average 65% reduction noted
  • 21% completely stopped using opioids

Opioid reductions were sustained through 14 months from the start of treatment, with 57% of participants reporting opioid reductions and 21% reporting complete cessation of opioids at the end of follow-up.

There were no study-related serious or unanticipated adverse events (AEs).

Adverse events related to the device or procedure that did occur were all non-serious (mild or moderate) and all adverse events were followed to resolution. The most common adverse events were mild skin irritation or pruritis (itching) at the site of the waterproof dressing or stimulator’s hydrogel mounting pad. One participant experienced a superficial skin infection at one lead exit site that was resolved by removal of the lead in the week prior to the end of treatment and use of an oral antibiotic.

Percutaneous PNS is a Promising First-Line Neurostimulation Treatment for Chronic Back Pain

In summary, the majority of the chronic back pain participants in this study reported clinically and statistically significant sustained reductions in pain, disability, and pain interference, as well as improvements in health-related quality of life and reduced usage of (or full cessation of) opioids.

“As we look toward pain treatment options for chronic back pain patients who are uncomfortable with surgery or more invasive procedures, percutaneous PNS offers a promising treatment option early in the care continuum,” said Dr. Christopher Gilmore. “The minimally invasive and temporary nature of the SPRINT PNS System is a winning factor when a patient is concerned about the risks usually associated with surgery as well as the long-term impact on quality of life when considering a permanently implanted system. The data we gathered in this study is a good foundation to help better educate patients while helping them feel comfortable with this treatment approach.”

Given the minimally invasive, non-destructive nature of percutaneous PNS and the significant benefits, percutaneous PNS may provide a promising first-line neurostimulation treatment for patients with chronic axial LBP.


[1] US Burden of Disease Collaborators. The State of US Health, 1990-2010 Burden of Diseases, Injuries, and Risk Factors. JAMA. 2013; 310(6):591-606.

Study and ASPN research abstract poster authors: Christopher A. Gilmore, MD, Mehul J. Desai, MD, MPH, Thomas J. Hopkins, MD, MBA,Sean Li, MD, Michael J. DePalma, MD, Timothy R. Deer, MD, Steven P. Cohen, MD, Meredith J. McGee, PhD, Joseph W. Boggs, PhD

Share this post:

Share on Twitter Share on Facebook Share on LinkedIn Share on SMS Share on Email
Category: NewsTag: Back Pain, back pain treatment, chronic back pain, low back pain, medial branch, multifidi, Non-opioid, opioid alternative, opioid reductions, pain reductions, pain relief, SPRINT PNS, SPRINT PNS System
Previous Post:SPRINT PNS - a new protocol of careMulti-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life
Next Post:SPR Therapeutics CEO Maria Bennett Selected as Winner of EY Entrepreneur of the Year in East Central RegionMaria Bennet EY Entrepreneur of the Year in East Central Region

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Sidebar

Archives

Recent News

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022

A Discussion on Pain Management Options for Patients with Breast Cancer with Dr. Amitabh Gulati

Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

Pain Medicine News Features SPRINT® PNS System Real-World Survey Outcomes

Tags

60-day percutaneous PNS acute pain Back Pain back pain treatment cancer pain chronic back pain Chronic Pain clinical study Dr. Mehul Desai drug-free EY award hip pain low back pain medial branch Neuromodulation Non-opioid oncological pain opioid alternative Pain pain appointment pain physician pain relief pain treatment Patients Patient Story peripheral nerve stimulation permanent PNS implant phantom limb pain PNS PNS training post-amputation pain Press release radiofrequency ablation recondition CNS reduced opioids research Research study residual limb pain RFA Shoulder Pain SPRINT PNS SPRINT PNS System temporary pns Training lab webinar
SPRINT® PNS System

22901 Millcreek Blvd, Suite 500
Cleveland, OH 44122
(844) 378-9108 Phone
(216) 803-0777 Fax

Top Work Places 2022

Quick Links

  • Product
  • For Physicians
  • For Patients
  • Clinical Trials
  • News & Events
  • Careers
  • About Us
  • Contact Us

Legal Links

  • Privacy Statement
  • Terms of Use
  • CPRA Requests
  • Important Safety Information
  • Compliance
  • FCOI Policy
  • Product Terms & Conditions
  • Patent Information

Recent News Headlines

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

NANS 26th Annual Meeting – Las Vegas, NV

Sprint Regional Lab – Jacksonville

Sprint Regional Lab – Chicago

The SPRINT PNS System is indicated for up to 60 days for: (i) Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) Symptomatic relief of post-traumatic pain; and (iii) Symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves. Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View References for support of all claims.

The SPRINT® PNS System, MicroLead™, OnePass Introducer™, Rethink Your Pain Strategy™, Outsmart Pain™, Sustained Pain Relief Starts Here™, Life. Get Back to It.™ and SPR® are registered or common law trademarks of SPR Therapeutics, Inc.


Copyright © 2023 SPR Therapeutics. All Rights Reserved.

This website is intended only for US and Canadian residents 18 years of age and older. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Save & Accept
Powered by CookieYes Logo